Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage.
J Neurol Neurosurg Psychiatry
; 89(5): 467-475, 2018 05.
Article
em En
| MEDLINE
| ID: mdl-29321140
ABSTRACT
BACKGROUND:
Differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) is not straightforward, especially in the early stages of disease. We compared AD biomarkers (phospho-Tau181, total-Tau, Aß42 and Aß40) in cerebrospinal fluid (CSF) of patients with DLB and AD, focusing especially on the prodromal stage.METHODS:
A total of 1221 CSF were collected in different memory centres (ePLM network) in France and analysed retrospectively. Samples were obtained from patients with prodromal DLB (pro-DLB; n=57), DLB dementia (DLB-d; n=154), prodromal AD (pro-AD; n=132) and AD dementia (n=783), and control subjects (CS; n=95). These centres use the same diagnostic procedure and criteria to evaluate the patients.RESULTS:
In patients with pro-DLB, CSF Aß42 levels appeared much less disrupted than in patients at the demented stage (DLB-d) (P<0.05 CS>pro-DLB; P<0.001 CS>DLB-d). On average, Aß40 levels in patients with DLB (pro-DLB and DLB-d) were much below those in patients with pro-AD (P<0.001 DLB groupsCONCLUSIONS:
Reduced levels of CSF Aß42 were found in patients with DLB but rather at a later stage, reaching those of patients with AD, in whom Aß42 levels were decreased even at the prodromal stage. At the prodromal stage of DLB, the majority of patients presented a normal CSF profile. CSF t-Tau and phospho-Tau181 were the best biomarkers to discriminate between AD and DLB, whatever the stage of disease.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doença por Corpos de Lewy
/
Doença de Alzheimer
/
Sintomas Prodrômicos
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
França